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The initial observation in 1973 that the complement C5 activation product, C5a, has the ability
to stimulate human neutrophils led to the concept of a specific C5a receptor (1). In the mid-
1986, a groundbreaking paper published in Nature announced the cloning of the beta-adrenergic
receptor, and for the first time established seven transmembrane (7TM)G protein-coupled receptors
as members of the rhodopsin superfamily (2). Almost simultaneously, Feltner and colleagues
demonstrated that the FMLP, C5a, and LTB4 activities on rabbit neutrophils could be inhibited
by pertussis toxin, indicating coupling to GTP binding proteins (3). In 1987, Masu and colleagues
used an oocyte expression cloning system to isolate a cDNA encoding the neuropeptide substance
K receptor; and later, the same group identified the related substance P receptor (4, 5).
In 1989, we realized that the pertussis sensitivity of the fMLP, C5a, and LTB4 receptors suggested
that they would also be members of the rhodopsin superfamily. When we aligned the handful
of structures for the then known 7TM receptors (adrenergic, serotonin, dopamine, FSH/LH, and
substance P and K receptors), we recognized homologies in both the transmembrane segments
and intracellular loops, which presumably facilitated interactions with G proteins. This observation
actually presented us with an opportunity to attempt to clone receptors by homology to the
superfamily as “orphan receptors.”
We constructed an antisense oligonucleotide withminimal degeneracy that encompassed a highly
conserved NPXXY motif in the seventh transmembrane segment of the known rhodopsin family
members. In order to enrich in C5a receptors, we took advantage of the fact that the receptors
were induced by cyclic-AMP in U937 cells, and in retinoic acid differentiated human HL60 cells.
By summer of 1990, we had isolated ~20 cDNAs using this approach from the cAMP induced
U937 cell library. About half of these clones were an identical cDNA that we named NPIIY-18.
Using this as a probe, we demonstrated that NPIIY-18 recognized a ~2.2 kb mRNA only in cAMP
differentiated U937 cells. Northern blot analyses showed that NPIIY-18 was present only in cells
known to express the C5a receptor. As NPIIY-18 was not a full-length cDNA, we then probed the
retinoic acid differentiated HL60 cell library. We isolated a full-length DNA from this library that
encoded a 7TM receptor with 25% homology to the substance K receptor and 35% homology to
the human fMLP receptor (FPR1), which was cloned by Francois Boulay in May 1990 (6). When
expressed in COS cells, we showed that NPIIY-18 encoded a high-affinity receptor for human C5a
(Figure 1) (7). This work was accepted for publication in Nature in December 1990. In the summary
paragraph of this manuscript, we pointed out that our approach should be helpful to clone the
receptors for the leukotrienes, platelet activating factor, interleukin-8, and adenosine receptors as
these are all present on cAMP differentiated U937 cells. Almost simultaneously, Francois Boulay
confirmed our identification of the human C5aR, which his group accomplished by expression
cloning of differentiated HL-60 cells (8). His work was published in March 1991, some 4months
after ours.
In November 1990, within months of the identification of the human FPR1, Thomas et al.
reported the cloning of the rabbit receptor for fMLP, F3R (9), which had almost no significant
homology to the human receptor. This was troubling, because we knew that when the ligand
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FIGURE 1 | Final steps in cloning and identifying the human C5a receptor. (A) Tertiary screen of clone NPIIY-18 using 32P-labeled oligonucleotide probe.
(B) NPIIY-18 was transfected into COS7 cells and tested for binding of 125 I-C5a under competitive binding conditions. (C) The resulting binding isotherm and
Scatchard analysis proving the clone’s identity.
was identical from species to species, the receptors were generally
highly conserved. Thus, the adrenergic, dopamine, serotonin, and
histamine receptors are >90% identical across species. Curiously,
the cDNA was reported to bind the FPR1 radioligand and trans-
duce calcium transients. Because the expression of the claimed
rabbit F3R formyl peptide receptor was restricted to neutrophils,
we wondered if, in fact, the Navarro lab had misidentified an
interleukin-8 receptor. One of us (Craig Gerard) actually traveled
to the Navarro lab to obtain the F3R cDNA to establish a collabo-
ration and test its identity as a receptor for IL-8. At that time, there
was no radioligand IL-8 commercially available. Henry Showell, of
Pfizer Central Research, was able to provide us with a custom iod-
inated IL-8, which we demonstrated to bind F3R. Unfortunately,
we did not have sufficient quantities of the reagent to perform
comprehensive studies to publish our findings. We disclosed our
result to Javier Navarro, but were left in silence. Unbeknownst to
us, DanWitt, at Repligen, had reportedly approached the Navarro
lab with a similar idea. Thomas et al. went on to publish F3R
as an IL8 receptor, without retracting the previous paper (10).
During this time, Tom Schall and I met at a FASEB meeting with
Phil Murphy, and suggested to him that he use F3R to clone a
human homolog from HL60 cells and test it against IL8. The
landmark Murphy and Tiffany paper resulted (11). Phil offered
one of us (Craig Gerard) coauthorship for the helpful suggestion
but because of intellectual property concerns at our institution, we
requested an acknowledgment instead.
Over the next decade, the orphan receptor approach led to
the identification of a wide variety of chemoattractant recep-
tors, including most of the chemokine receptor system. The
most notable events in the area of chemokines occurred when
CXCR4 and CCR5 were identified as HIV coreceptors. It was
known from the work of Ed Berger that CXCR4 was the obli-
gate coreceptor with CD4 for laboratory-adapted strains of HIV
(12). However, the wild type, the so-called macrophage tropic
strain used an unknown coreceptor. In December 1995, it was
reported in the New York Times that the Gallo laboratory had
identified Mip1α, Mip1β, and RANTES as substances that inhib-
ited HIV infections (13). Coincidentally, at the Fourth Inter-
national Chemokine Symposium, held June 27–30, 1995, Izzy
Charo described an orphan receptor identified as CCR5, linked
to CCR2, which bound Mip1α, Mip1β, and RANTES (14). Thus,
an international race began as five chemokine labs partnered
with HIV labs to prove the hypothesis that CCR5 was the HIV
coreceptor.
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